Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia

Philip M Clarke and Edmund M FitzGerald
Med J Aust 2010; 193 (3): . || doi: 10.5694/j.1326-5377.2010.tb03850.x
Published online: 2 August 2010

In reply: Our recent study1 estimates pharmaceutical expenditure from 2009 to 2019 for various levels of use of off-patent statins, ranging from 25% (close to the current proportion) to 100%. We also show that England has much higher use of generic statins and consequently much lower pharmaceutical expenditure. However, our study does not advocate a particular level of generic use and so it is unclear why Bulfone has chosen to focus on only one of the cases (100% use of generics) presented in our study.

  • Philip M Clarke
  • Edmund M FitzGerald

  • School of Public Health, University of Sydney, Sydney, NSW.



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.